The "Prenatal Diagnosis Panel 1 Chorionic Villus Biopsy Test" is a sophisticated diagnostic procedure offered by DNA Labs UAE, aimed at expectant parents who wish to assess the genetic health of their fetus early in the pregnancy. Priced at 9360 AED, this test involves collecting a small sample of chorionic villi, which are tiny finger-like projections found on the placenta. The sample is then analyzed to detect any chromosomal abnormalities or genetic disorders in the fetus, such as Down syndrome, cystic fibrosis, or sickle cell anemia, among others.
Performed between the 11th and 14th weeks of pregnancy, this invasive procedure is recommended for those with a high risk of genetic disorders, including families with a history of genetic conditions, parents with chromosomal abnormalities, or older mothers. Despite its invasive nature, the test provides highly accurate and early insights into the fetus's genetic health, enabling informed decisions and preparations for the future. DNA Labs UAE ensures the procedure is conducted with the utmost care and precision, leveraging advanced technologies and expertise to minimize risks and provide comprehensive support to the expectant parents.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 5 Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to assess the compatibility between organ transplant donors and recipients, with a focus on individuals who are highly sensitized. This test is crucial for identifying potential human leukocyte antigen (HLA) mismatches that could lead to transplant rejection, a common concern for sensitized recipients who have developed antibodies against foreign HLA due to previous transplants, blood transfusions, or pregnancies.
The panel involves a comprehensive screening for antibodies against HLA, providing a detailed profile that helps in the selection of a compatible donor, thereby increasing the success rate of the transplant. This advanced immunological assessment plays a pivotal role in the pre-transplant evaluation process, guiding clinicians in their decision-making to minimize the risk of acute or chronic rejection episodes.
Priced at 7800 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, which is equipped with the latest technologies and staffed by experienced professionals. This investment is vital for sensitized patients awaiting transplants, as it significantly enhances the likelihood of a successful outcome by facilitating the identification of a suitable donor match, ultimately improving patient survival and quality of life post-transplant.
The Non-Invasive Prenatal Paternity (NIPT) DNA Test is a groundbreaking procedure offered by DNA Labs UAE, designed to determine paternity with high accuracy during pregnancy. This test is non-invasive, meaning it poses no risk to the mother or the unborn child, as it requires only a blood sample from the expectant mother and a simple swab from the potential father. The test works by analyzing the baby's DNA found within the mother's bloodstream, comparing it to the DNA of the potential father. This advanced technology can be performed as early as the 7th week of pregnancy, providing early and reliable answers about paternity.
The cost of the NIPT Pregnancy Paternity DNA Test at DNA Labs UAE is 7000 AED. This price reflects the sophisticated technology and expertise required to accurately analyze and interpret the results. Opting for this test at DNA Labs UAE ensures a high level of accuracy, confidentiality, and professional support throughout the process. This option is particularly appealing for families seeking early paternity confirmation, without the risks associated with invasive testing methods.
The Oncomine Comprehensive Panel, along with the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Test, is an advanced genetic testing suite designed for a comprehensive analysis of cancer genomes. Offered by DNA Labs in the UAE, this suite of tests provides a detailed overview of the genetic alterations in tumors, aiding in the personalized treatment of cancer patients.
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that identifies DNA and RNA changes across a wide array of cancer-related genes. This broad-spectrum analysis helps in understanding the molecular underpinnings of an individual's cancer, facilitating targeted therapy decisions.
The Oncomine TMB test quantifies the total number of mutations within a tumor genome, providing an index of the tumor's mutation burden. A high TMB is often associated with better responses to immunotherapies, making this test crucial for therapy selection.
The MSI test assesses the status of microsatellite instability in cancer cells, which is a condition of genetic hypermutability that results from the impairment of DNA mismatch repair. MSI status is a key biomarker in certain types of cancers, such as colorectal cancer, and influences treatment choices.
The PD-L1 test measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 is a checkpoint protein that helps cancers evade the immune system. Knowing the PD-L1 status can guide the use of checkpoint inhibitor therapies, which can be effective in treating various types of cancer.
Conducted at DNA Labs in the UAE, the comprehensive suite of these tests is priced at 24,000 AED. This investment in precision medicine can significantly impact treatment strategies, offering hope for better outcomes by tailoring therapies to the specific genetic profile of a patient's tumor.
The Oncopro NCCN Lung Cancer Panel Test, available at DNA Labs UAE, is a cutting-edge diagnostic tool designed to aid in the personalized treatment of lung cancer. This comprehensive test, priced at 23,400 AED, employs next-generation sequencing technology to analyze a patient's tumor sample for specific genetic mutations and biomarkers identified by the National Comprehensive Cancer Network (NCCN) guidelines as relevant to lung cancer care. By pinpointing these unique genetic alterations, the test enables healthcare providers to tailor treatment strategies to the individual patient, potentially improving outcomes and reducing the likelihood of unnecessary side effects. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in the precision medicine approach to lung cancer treatment, offering hope for more effective and personalized care.
The "Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test" is a specialized diagnostic procedure designed to detect resistance mutations in the NS5a region of the hepatitis C virus (HCV) genotype 1. This test is particularly crucial for tailoring the most effective antiviral therapy for individuals infected with HCV, as resistance mutations can significantly impact the efficacy of treatment regimens. The test involves analyzing the viral RNA to identify specific mutations within the NS5a protein, which plays a key role in the virus's replication process and its resistance to NS5a inhibitor drugs.
Given the complexity and precision required for this test, it is performed at specialized laboratories equipped with advanced molecular diagnostic technologies. In the UAE, DNA Labs UAE is one of the facilities offering this cutting-edge test, ensuring high accuracy and reliability in the results. The cost for undergoing the Hepatitis C Viral RNA Genotype 1 NS5a Drug Resistance Test at DNA Labs UAE is 12,000 AED. This investment is crucial for optimizing the management and treatment of HCV, particularly for patients with genotype 1, the most common and often the most challenging to treat variant of the virus. By identifying the presence of drug resistance mutations, healthcare providers can make informed decisions on the most appropriate and effective treatment strategies, potentially improving patient outcomes and reducing the risk of treatment failure.
The "Can Assist Breast Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to evaluate the risk of breast cancer by analyzing genetic markers. This test, priced at 15,680 AED, utilizes advanced genetic sequencing technologies to assess the individual's susceptibility to breast cancer. It examines specific DNA segments for mutations and variations that are known to increase the risk of developing the disease. By providing personalized risk assessment, the "Can Assist Breast Test" aids in early detection and enables patients and healthcare providers to make informed decisions about preventive measures and tailored screening schedules. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in personalized medicine and cancer prevention strategies.
The "Oncopro 350 Gene TMB and MSI Profile Test" is a sophisticated diagnostic tool available at DNA Labs UAE, designed to provide comprehensive insights into the genetic profile of a patient's cancer. Priced at 15,210 AED, this test screens for mutations across 350 cancer-related genes, alongside assessing Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status. These metrics are crucial for understanding the behavior of cancer at a molecular level, guiding personalized treatment strategies. The TMB evaluation helps in determining the likelihood of response to immunotherapy, while MSI status can indicate susceptibility to certain types of cancer treatments. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a critical step towards tailored cancer care, offering hope for more effective and targeted therapy options.
The Oncopro Tumor Mutation Burden (TMB) Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to assess the number of mutations within a tumor's DNA. This test plays a crucial role in the field of oncology, as the Tumor Mutation Burden is a biomarker that can predict how well a patient might respond to certain immunotherapies. By evaluating the quantity of mutations, the test can help oncologists tailor more effective and personalized treatment plans for patients with various types of cancer.
The test involves a comprehensive analysis of the tumor tissue to quantify the mutation burden, providing valuable insights into the tumor's behavior and its potential response to treatment. This information is pivotal for determining the suitability of immunotherapy, which works by empowering the patient's immune system to recognize and combat cancer cells more effectively.
Administered at DNA Labs UAE, a facility known for its advanced diagnostic technologies and precision medicine, the Oncopro TMB Test is available for a cost of 14,040 AED. This investment can be a crucial step for patients seeking personalized cancer therapy options, offering a beacon of hope for improved treatment outcomes by leveraging the power of genetic insights to combat cancer.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 4 Test" is a specialized diagnostic procedure conducted at DNA Labs UAE, designed to evaluate potential transplant recipients for sensitization to human leukocyte antigens (HLA). This test is crucial for identifying individuals who have developed antibodies against HLA, which can significantly impact the success rate of organ transplants. Sensitization can occur due to previous transplants, blood transfusions, or pregnancies, making it essential to assess the compatibility between donor and recipient to minimize the risk of organ rejection.
The test involves a comprehensive analysis of the recipient's immune response to various HLA antigens, providing invaluable information for the medical team to make informed decisions regarding transplantation strategies. The cost of this detailed and critical assessment is 14,040 AED, reflecting the sophisticated technology and expertise required to conduct the test and interpret its results. Conducted at DNA Labs UAE, a facility known for its state-of-the-art technology and highly qualified professionals, this test is a vital step in the pre-transplant evaluation process, ensuring the highest possible success rates for organ transplants by identifying and addressing potential challenges related to HLA sensitization.
